Search results for "Antibodies."

showing 10 items of 1857 documents

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccinatio…

2009

Priming a population with a pre-pandemic vaccine is being considered to maximize the response upon subsequent vaccination with a true pandemic vaccine more closely matched to the causative pandemic strain. The present study explored this prime-boost concept by evaluating different primary schedules with the pre-pandemic A/Vietnam/1194/2004(NIBRG-14) vaccine, containing 3.75 microg of HA, followed by a 6-month booster with a vaccine formulated with 3.75 microg HA of either the same strain or with A/Indonesia/05/2005(IBCDC-RG2), a heterologous strain from a different clade. In this multicentre, open, randomized study (NCT00430521) we measured immune responses in four groups (N = 48-60) of adu…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCross Protectionmedicine.medical_treatmentPopulationImmunization SecondaryBooster doseAntibodies ViralYoung AdultAdjuvants ImmunologicImmunityInfluenza Humanparasitic diseasesmedicineHumansAS03educationeducation.field_of_studyBooster (rocketry)Influenza A Virus H5N1 SubtypeGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthHemagglutination Inhibition TestsMiddle AgedImmunity HumoralVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

The impact of ten years of infant universal Varicella vaccination in Sicily, Italy (2003-2012).

2015

Introduction Universal varicella vaccination in Sicily was introduced in infant population since 2003, with a rapidly increasing coverage. Aim of the present study was to analyze changes in the epidemiology of varicella since the introduction of universal vaccination. Methods The study was performed by analyzing Sicilian administrative/clinical data on varicella case notifications and hospitalizations from 2003 to 2012 (ICD-9-CM discharge diagnosis codes 052 and 052.×). MMR+V and V coverage were also calculated for each birth cohort. Moreover, blood samples drawn in 2013/2014 from general population stratified by age were tested for varicella antibodies. Results From 2003 to 2012, 15 433 va…

AdultMalePediatricsmedicine.medical_specialtyAdolescentImmunologyPopulationSocio-culturalecoverageVaricella vaccinationAntibodies ViralSettore MED/42 - Igiene Generale E ApplicataChickenpox VaccineYoung AdultChickenpoxvaricellaEpidemiologyHumansImmunology and AllergyMedicineYoung adultChildeducationDisease NotificationSicilyChickenpox VaccineHospitalizationsPharmacologyeducation.field_of_studyChickenpoxbusiness.industryVaccinationInfant NewbornInfantNotificationsmedicine.diseaseHospitalizationVaccinationCoverage; Epidemiology; Hospitalizations; Notifications; Sicily; Universal mass vaccination; VaricellaChild PreschoolFemaleepidemiologynotificationbusinessBirth cohortuniversal mass vaccinationHumanResearch Paperhospitalization
researchProduct

Improvement in quality of life with omalizumab in patients with severe allergic asthma.

2006

Patients with severe persistent asthma experience daily symptoms and frequent serious exacerbations that contribute to a significant impairment of health-related quality of life (QoL).A pooled analysis was completed of six controlled clinical trials that evaluated the effect of add-on omalizumab on asthma-related QoL in patients with severe persistent allergic (IgE-mediated) asthma. Asthma-related QoL was assessed at baseline and treatment endpoint using the well-validated Juniper Asthma Quality of Life Questionnaire (AQLQ). Change from baseline in AQLQ total score was compared between treatments using analysis of covariance methods. The percentage of patients who achieved a clinically mean…

AdultMalePediatricsmedicine.medical_specialtyAdolescentOmalizumabOmalizumabAntibodies Monoclonal HumanizedSeverity of Illness IndexQuality of lifeSeverity of illnessHypersensitivityMedicineHumansIn patientAnti-Asthmatic AgentsChildAsthmaAgedRandomized Controlled Trials as Topicbusiness.industryAntibodies MonoclonalAllergic asthmaGeneral MedicineMiddle Agedmedicine.diseasehumanitiesAsthmaAntibodies Anti-IdiotypicClinical trialMeta-analysisQuality of LifeFemalebusinessmedicine.drugCurrent medical research and opinion
researchProduct

Immunity to tetanus in the 3-20 year age group in Italy

1997

In Italy, systematic mandatory tetanus immunization of children started in 1968. In 1989, immunity against tetanus was assessed in a random sample of 758 healthy subjects aged 3-20 y, from four Italian cities. There were 257 subjects 3-5 y old all residing in Southern Italy and 501 subjects 11-20 y old from both the South and North. The overall prevalence of non-immune subjects was 19.1%, without difference by sex. The rates of subjects lacking protective antibody titres was 25.3% in children 3-5 y old (all coming from South and the islands), 11.5% in those 11 y old, and 18.9% in the 18-20 y age-group, respectively. Subjects 11-20 y old residing in the South and the islands were more likely…

AdultMalePediatricsmedicine.medical_specialtyAdolescentTetanus immunizationTetanus.ImmunitymedicinePrevalenceTetanus ToxoidHumansChildHigh rateTetanusTetanusbusiness.industryPublic Health Environmental and Occupational HealthHealthy subjectsImmunityGeneral Medicinemedicine.diseaseAntibodies BacterialVaccinationItalyChild PreschoolFemaleProtective antibodyGeographical inequalitiesbusiness
researchProduct

Clinical and therapeutic features of myasthenia gravis in adults based on age at onset

2020

[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG).

AdultMalePediatricsmedicine.medical_specialtyThymomagenetic structuresCross-sectional studyInvestigación médicaEnfermedad del sistema nerviosoMEDLINEMiastenia gravisLate onsetDISEASECLASSIFICATIONArticleACETYLCHOLINE-RECEPTOR03 medical and health sciences0302 clinical medicineimmune system diseasesMyasthenia GravismedicineEnfermedades neuromuscularesHumansRITUXIMAB030212 general & internal medicineAge of OnsetAgedbusiness.industryAnálisis de datosMiddle Agedmedicine.diseaseMyasthenia gravisnervous system diseasesCross-Sectional StudiesTreatment OutcomeMulticenter studyANTIBODIESAUTOANTIBODIESFemaleObservational studyNeurology (clinical)Age of onsetbusiness030217 neurology & neurosurgeryMUSK
researchProduct

Identification of a peptide mimicking the binding pattern of an antiphospholipid antibody

2006

Our objective was to characterize monoclonal antiphospholipid antibodies (APL) and identify disease-associated antigens in patients with the antiphospholipid syndrome (APS). We used the monoclonal antibody HL-5B, derived from a patient with APS suffering from multiple ischemic events, to screen a 12-mer peptide phage display library (New England Biolabs, London, England). The identified phage clones were sequenced and the derived consensus peptide was synthesized. The peptide was used to perform competitive inhibition experiments for their ability to inhibit the binding of the monoclonal antibody and of serum antibodies to cardiolipin and phosphatidylserine. Additionally patients and contro…

AdultMalePhage displaymedicine.drug_classMolecular Sequence DataImmunologyEnzyme-Linked Immunosorbent AssayMonoclonal antibodyEpitopeAntigenAntibody SpecificityPeptide LibraryAntiphospholipid syndromemedicineHumansImmunology and AllergyAmino Acid SequencePeptide libraryPeptide sequenceAgedbiologyMolecular MimicryAntibodies MonoclonalHematologyMiddle AgedAntiphospholipid Syndromemedicine.diseaseVirologyMolecular biologyAntibodies Antiphospholipidbiology.proteinFemaleAntibodyPeptidesProtein BindingImmunobiology
researchProduct

Accuracy of two plasma antibody tests and faecal antigen test for non-invasive detection of H. pylori in middle-aged Caucasian general population sam…

2018

The aim of the study was to assess the accuracy of two plasma Helicobacter pylori (H. pylori) antibody test-systems and a stool antigen test (SAT) system in a general population sample in Latvia.Blood and faecal samples were analysed in healthy individuals (40-64 years), referred for upper gastrointestinal endoscopy according to pilot study protocol within a population-based study investigating gastric cancer prevention strategies (GISTAR pilot study). Antibodies to H. pylori were assessed in plasma by latex-agglutination test and enzyme-linked immunosorbent assay (ELISA). H. pylori antigen in faecal samples was detected by a monoclonal enzyme immunoassay-based SAT. Histological assessment …

AdultMalePopulation sampleEnzyme-Linked Immunosorbent AssayPilot ProjectsSensitivity and SpecificityHelicobacter Infections03 medical and health sciencesFeces0302 clinical medicineMedicineHumansSerologic TestsAntigens BacterialbiologyHelicobacter pyloribusiness.industryNon invasiveGastroenterologyHelicobacter pyloriMiddle Agedbacterial infections and mycosesbiology.organism_classificationAntigen testAntibodies BacterialLatex fixation testROC Curve030220 oncology & carcinogenesisImmunologybiology.proteinStool antigen030211 gastroenterology & hepatologyFemaleFranceAntibodybusinessScandinavian journal of gastroenterology
researchProduct

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4

2008

We investigated the mechanisms involved in the resistance to cell death observed in epithelial cancers. Here, we identify that primary epithelial cancer cells from colon, breast and lung carcinomas express high levels of the antiapoptotic proteins PED, cFLIP, Bcl-xL and Bcl-2. These cancer cells produced interleukin-4 (IL-4), which amplified the expression levels of these antiapoptotic proteins and prevented cell death induced upon exposure to TRAIL or other drug agents. IL-4 blockade resulted in a significant decrease in the growth rate of epithelial cancer cells and sensitized them, both in vitro and in vivo, to apoptosis induction by TRAIL and chemotherapy via downregulation of the antia…

AdultMaleProgrammed cell deathLung NeoplasmsTime Factorsapoptosis interleukin-4 cancer stem cells cancer chemiotherapy cytokinesCASP8 and FADD-Like Apoptosis Regulating Proteinbcl-X ProteinAntineoplastic AgentsApoptosisBreast NeoplasmsBiologyTNF-Related Apoptosis-Inducing LigandTumor Cells CulturedmedicineHumansAutocrine signallingMolecular BiologyInterleukin 4AgedCell ProliferationSettore MED/04 - Patologia GeneraleCell DeathDose-Response Relationship DrugCell growthCarcinomaIntracellular Signaling Peptides and ProteinsAntibodies MonoclonalInterleukin-4 Receptor alpha SubunitCorrectionCancerCell BiologyMiddle AgedPhosphoproteinsmedicine.diseaseUp-RegulationCell biologyAutocrine CommunicationProto-Oncogene Proteins c-bcl-2Drug Resistance NeoplasmApoptosisColonic NeoplasmsCancer cellFemaleInterleukin-4Interleukin-4 Cancer stem cellsSignal transductionApoptosis Regulatory ProteinsSignal Transduction
researchProduct

Identification of Biomarkers in Cerebrospinal Fluid and Serum of Multiple Sclerosis Patients by Immunoproteomics Approach

2014

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system. At present, the molecular mechanisms causing the initiation, development and progression of MS are poorly understood, and no reliable proteinaceous disease markers are available. In this study, we used an immunoproteomics approach to identify autoreactive antibodies in the cerebrospinal fluid of MS patients to use as candidate markers with potential diagnostic value. We identified an autoreactive anti-transferrin antibody that may have a potential link with the development and progression of MS. We found this antibody at high levels also in the serum of MS patients and created an immun…

AdultMaleProteomicsPathologymedicine.medical_specialtyImmunoproteinsimmunoproteomeCentral nervous systemDiseaseBiologymultiple sclerosisProteomicsArticlecerebrospinal fluidCatalysisImmunoproteomicslcsh:ChemistryInorganic ChemistryCerebrospinal fluidSettore BIO/13 - Biologia ApplicatamedicineHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyMultiple sclerosisOrganic ChemistryTransferrinCase-control studyGeneral MedicineMiddle Agedmedicine.diseaseComputer Science Applicationsmedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Case-Control Studiesmultiple sclerosiserum biomarkerImmunologyanti-transferrin autoantibodiesbiology.proteinFemaleSettore MED/26 - Neurologiaanti-transferrin autoantibodieAntibodyBiomarkersInternational Journal of Molecular Sciences
researchProduct

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

2015

Abstract Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms including compensatory ligand upregulation and de novo gene alterations. Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes. In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the presence of ligands. In this phase I trial, we observed grade 3 skin toxicity and hypomagnesemia as mechanism-based dose-limiting events during dose escalation. In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhi…

AdultMaleProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Antineoplastic AgentsContext (language use)Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]LigandsPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundCell Line TumorHumansMedicinePanitumumabNeoplasm MetastasisAgedEGFR inhibitorsAged 80 and overDose-Response Relationship DrugCetuximabbusiness.industryGene AmplificationAntibodies MonoclonalCancerMiddle Agedmedicine.diseaseErbB ReceptorsClinical trialGenes rasTreatment OutcomeOncologychemistryMutationImmunologyCancer researchFemaleGrowth inhibitionColorectal Neoplasmsbusinessmedicine.drug
researchProduct